Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Nanning Maple Leaf Pharmaceutical Co., Ltd. is a Chinese pharmaceutical company and a wholly-owned subsidiary of WEX Pharmaceuticals Inc., which is part of the CK Life Sciences group. Based in Nanning, Guangxi, the company serves as the primary manufacturing and research facility for the development of Tetrodotoxin (TTX), a potent sodium channel blocker derived from pufferfish. Its lead product candidate, Tectin (also known as Halneuron), is being evaluated in late-stage clinical trials for the treatment of moderate to severe cancer-related pain and chemotherapy-induced neuropathic pain. In addition to its specialized work with marine toxins, the company has historically manufactured and marketed generic pharmaceutical products in the Chinese market.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Nanning Maple Leaf Pharmaceuticals.